US NIH launches long-COVID trials of Pfizer's Paxlovid, other therapies
Reuters
Published Jul 31, 2023 12:08PM ET
Updated Jul 31, 2023 01:22PM ET
(Reuters) - The U.S. National Institutes of Health (NIH) said on Monday that it had launched mid-stage clinical trials to test at least four treatments, including Pfizer (NYSE:PFE)'s Paxlovid, in patients with symptoms of long COVID.
The studies are designed to evaluate multiple therapies, where the first part of trial will test a longer dosing regimen of the antiviral COVID-19 drug Paxlovid to see if it improves long COVID symptoms.
The complex medical condition involves more than 200 symptoms ranging from exhaustion and cognitive impairment to pain, fever and heart palpitations that can last for months and even years following a COVID-19 infection.
NIH said other parts of the study will also test for brain fog and memory problems related symptoms.
It will use medical treatments like a web-based brain training program called BrainHQ by San Franscisco-based private company Posit Science Corp and Soterix Medical Inc's device that uses a small electric current to stimulate brain activity, the health agency added.
Additional clinical trials are expected to be launched to test not less than seven more treatments, it said.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.